45 research outputs found
Salinomycin and virginiamycin for lactating cows supplemented on pasture
Animals on pasture generally show higher feed efficiency as a result of the use of antibiotics. This study evaluated the effect of the antimicrobials salinomycin and/or virginiamycin on production and the ruminal parameters of supplemented dairy cows grazing on Panicum maximum cv. Tanzania. Twelve Holstein/Zebu multiparous cows were used, distributed in three Latin squares, one for the evaluation of ruminal parameters, and the others for production parameters. Cows on pasture were fed 50 % of their estimated intake with corn silage and concentrate supplements containing salinomycin, virginiamycin or a combination of additives, in doses of 120 and 150 mg kg−1, respectively. There were no differences in milk production and composition, energy and nitrogen balance, dry matter digestibility and feeding behavior. However, salinomycin and virginiamycin each reduced pasture and total dry matter intake by about 14 % and 10 %, with a consequent improvement in feed efficiency
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background:
In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
Findings:
Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001).
Interpretation:
In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Background:
Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
Findings:
Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79).
Interpretation:
In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Educational Research and Intertextual Forms of (Re)Presentation: The case for Dancing the Data
Contemporary dialogues concerning qualitative methodology focus increasingly on alternative forms of data (re)presentation. This article explores the use of dance as a medium for such (re)presentation. The article contextualizes, describes, and reflects on a performance by the authors staged at the 1998 Annual Conference of the American Educational Research Association. The (re)presentation in words and movement was choreographed from research on school choice policy and its impact on families whose children have special educational needs, undertaken by one of the authors in the United Kingdom. In reflecting on the process, the article discusses some of the difficulties and advantages derived from the performance and stresses the need for creating a space for intertextual forms of data (re)presentation within the academy
HST Grism-derived Forecasts for Future Galaxy Redshift Surveys
The mutually complementary Euclid and Roman galaxy redshift surveys will use H\u3b1-and [O iii]-selected emission-line galaxies (ELGs) as tracers of the large-scale structure at 0.9 72 z 72 1.9 (H\u3b1) and 1.5 72 z 72 2.7 ([O iii]). It is essential to have a reliable and sufficiently precise knowledge of the expected numbers of H\u3b1-emitting galaxies in the survey volume in order to optimize these redshift surveys for the study of dark energy. Additionally, these future samples of ELGs will, like all slitless spectroscopy surveys, be affected by a complex selection function that depends on galaxy size and luminosity, line equivalent width (EW), and redshift errors arising from the misidentification of single ELGs. Focusing on the specifics of the Euclid survey, we combine two slitless spectroscopic WFC3-IR data sets-3D-HST+AGHAST and the WFC3 Infrared Spectroscopic Parallel survey-to construct a Euclid-like sample that covers an area of 0.56 deg2 and includes 1277 ELGs. We detect 1091 ( 3c3270 deg-2) H\u3b1+[N ii]-emitting galaxies in the range 0.9 64 z 64 1.6 and 162 ( 3c440 deg-2) [O iii] \u3bb5007 emitters over 1.5 64 z 64 2.3 with line fluxes 652
7 10-16 erg s-1 cm-2. The median of the H\u3b1+[N ii] EW distribution is 3c250 \uc5, and the effective radii of the continuum and H\u3b1+[N ii] emission are correlated with a median of 3c0.\u203338 and significant scatter (\u3c3 3c 0.\u20332-0.\u203335). Finally, we explore the prevalence of redshift misidentification in future Euclid samples, finding potential contamination rates of 3c14%-20% and 3c6% down to 2
7 10-16 erg s-1 cm-2 and 6
7 10-17 erg s-1 cm-2, respectively, although with increased wavelength coverage these percentages drop to nearly zero
Recommended from our members
Semi-analytic forecasts for Roman – the beginning of a new era of deep-wide galaxy surveys
The Nancy Grace Roman Space Telescope, NASA’s next flagship observatory, will redefine deep-field galaxy survey with a field of view two orders of magnitude larger than Hubble and an angular resolution of matching quality. These future deep-wide galaxy surveys necessitate new simulations to forecast their scientific output and to optimize survey strategies. In this work, we present five realizations of 2-deg2 light cones, containing a total of ≳25 million simulated galaxies with −16 ≳ MUV ≳ −25 spanning z ∼ 0 to 10. This data set enables a new set of experiments with the impacts of survey size on the derived galaxy formation and cosmological constraints. The intrinsic and observable galaxy properties are predicted using a well-established, physics-based semi-analytic modelling approach. We provide forecasts for number density, cosmic SFR, field-to-field variance, and angular two-point correlation functions, and demonstrate how the future wide-field surveys will be able to improve these measurements relative to current generation surveys. We also present a comparison between these light cones and others that have been constructed with empirical models. The mock light cones are designed to facilitate the exploration of multi-instrument synergies and connecting with current generation instruments and legacy surveys. In addition to Roman, we also provide photometry for a number of other instruments on upcoming facilities, including Euclid and Rubin, as well as the instruments, that are part of many legacy surveys. Full object catalogues and data tables for the results presented in this work are made available through a web-based, interactive portal. © 2022 The Author(s)Immediate accessThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]